CalciMedica, Inc.
Support and Resistance Levels
Past performance
News About CALC
All events for CALC
All deals for CALC
Financial Ratios
Financial Statements
CALC vs Sector & Peers
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury. Website calcimedica.com
Headquarters La Jolla, CA, US